Total Payments
$8,854
2024 Payments
$304.88
Companies
48
Transactions
366
Medicare Patients
1,828
Medicare Billing
$320,955
Payment Breakdown by Category
Food & Beverage$8,283 (93.6%)
Education$570.75 (6.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,283 | 351 | 93.6% |
| Education | $570.75 | 15 | 6.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,162 | 37 | $0 (2023) |
| Incyte Corporation | $684.10 | 10 | $0 (2023) |
| Janssen Biotech, Inc. | $594.16 | 23 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $530.36 | 13 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $520.52 | 36 | $0 (2024) |
| Merck Sharp & Dohme LLC | $468.52 | 32 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $462.59 | 7 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $450.18 | 13 | $0 (2024) |
| Eisai Inc. | $378.66 | 11 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $297.14 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $304.88 | 16 | Novartis Pharmaceuticals Corporation ($45.27) |
| 2023 | $1,421 | 55 | JAZZ PHARMACEUTICALS INC. ($209.87) |
| 2022 | $824.68 | 13 | JAZZ PHARMACEUTICALS INC. ($164.44) |
| 2021 | $1,002 | 10 | Incyte Corporation ($226.41) |
| 2020 | $945.82 | 37 | Incyte Corporation ($220.14) |
| 2019 | $2,511 | 120 | Amgen Inc. ($524.69) |
| 2018 | $918.27 | 55 | Amgen Inc. ($316.42) |
| 2017 | $926.47 | 60 | Astellas Pharma US Inc ($188.11) |
All Payment Transactions
366 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Oncology | ||||||
| 09/30/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.31 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: Oncology | ||||||
| 04/30/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: Immunology | ||||||
| 03/25/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $25.85 | General |
| Category: Oncology | ||||||
| 03/25/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: Oncology | ||||||
| 03/20/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: Oncology | ||||||
| 03/11/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: ONCOLOGY | ||||||
| 02/05/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: Oncology | ||||||
| 02/02/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: Iron Deficiency Anemia | ||||||
| 01/26/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Oncology | ||||||
| 01/24/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $17.94 | General |
| 01/16/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $21.82 | General |
| 01/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $13.62 | General |
| 01/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $19.29 | General |
| 12/18/2023 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: Oncology | ||||||
| 12/13/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Oncology | ||||||
| 12/11/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $7.20 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: Oncology | ||||||
| 11/21/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $70.09 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2023 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: Oncology | ||||||
| 11/06/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $10.84 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 373 | 594 | $122,359 | $44,578 |
| 2022 | 11 | 487 | 933 | $316,092 | $96,622 |
| 2021 | 11 | 529 | 1,018 | $326,688 | $100,467 |
| 2020 | 11 | 439 | 906 | $295,983 | $79,289 |
Total Patients
1,828
Total Services
3,451
Medicare Billing
$320,955
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 119 | 216 | $49,186 | $17,192 | 35.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 100 | $13,568 | $5,963 | 43.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 34 | 36 | $14,088 | $4,708 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 80 | $12,147 | $4,168 | 34.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 27 | $8,301 | $3,217 | 38.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $9,491 | $3,014 | 31.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 26 | 62 | $4,618 | $2,323 | 50.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $6,192 | $2,201 | 35.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 17 | $4,548 | $1,667 | 36.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 14 | 15 | $220.23 | $126.00 | 57.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 136 | 416 | $92,947 | $29,608 | 31.9% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 23 | 24 | $87,360 | $24,959 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 62 | 150 | $45,274 | $15,831 | 35.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 44 | 48 | $20,747 | $7,204 | 34.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 45 | 45 | $19,449 | $5,682 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 71 | 104 | $15,608 | $4,774 | 30.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 43 | $9,548 | $3,321 | 34.8% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 23 | 24 | $13,500 | $2,383 | 17.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $8,578 | $1,985 | 23.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 15 | 29 | $2,593 | $803.56 | 31.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 24 | 25 | $487.50 | $71.49 | 14.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 147 | 423 | $94,511 | $30,502 | 32.3% |
| 78815 | Nuclear medicine study with ct imaging skull base to mid-thigh | Office | 2021 | 25 | 26 | $94,640 | $26,464 | 28.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 46 | 101 | $30,534 | $11,171 | 36.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 109 | 186 | $27,915 | $8,864 | 31.8% |
About Dr. Michel Bidros, M.D
Dr. Michel Bidros, M.D is a Internal Medicine healthcare provider based in London, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2008. The National Provider Identifier (NPI) number assigned to this provider is 1609036227.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michel Bidros, M.D has received a total of $8,854 in payments from pharmaceutical and medical device companies, with $304.88 received in 2024. These payments were reported across 366 transactions from 48 companies. The most common payment nature is "Food and Beverage" ($8,283).
As a Medicare-enrolled provider, Bidros has provided services to 1,828 Medicare beneficiaries, totaling 3,451 services with total Medicare billing of $320,955. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Hospitalist
- Location London, KY
- Active Since 06/17/2008
- Last Updated 05/12/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1609036227
Products in Payments
- JAKAFI (Drug) $491.64
- ZEPZELCA (Drug) $462.59
- KEYTRUDA (Biological) $400.82
- DARZALEX (Biological) $337.71
- OPDIVO (Biological) $275.01
- IMBRUVICA (Drug) $245.88
- Kyprolis (Drug) $234.15
- IMFINZI (Biological) $229.94
- Kyprolis (Biological) $213.45
- INJECTAFER (Drug) $212.24
- Imbruvica (Drug) $209.64
- Lenvima (Drug) $203.88
- PEMAZYRE (Drug) $192.46
- KISQALI (Drug) $156.92
- REBLOZYL (Biological) $153.38
- ELITEK (Drug) $142.41
- CALQUENCE (Drug) $141.59
- IBRANCE (Drug) $139.80
- FOUNDATIONONE (Device) $139.24
- Neulasta (Biological) $128.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in London
Mark Adams, M.d, M.D
Internal Medicine — Payments: $195,977
Internal Medicine $195,977
Nancy Morris, M.d, M.D
Internal Medicine — Payments: $20,207
Internal Medicine $20,207
Bryon Cook, M.d, M.D
Internal Medicine — Payments: $4,396
Internal Medicine $4,396
Kamran Mahmood, Md, MD
Internal Medicine — Payments: $3,304
Internal Medicine $3,304
Syed Mustafa, Md, Mbbs, MD, MBBS
Internal Medicine — Payments: $2,734
Internal Medicine $2,734
Dr. Emily White, M.d, M.D
Internal Medicine — Payments: $1,579
Internal Medicine $1,579